PACLITAXEL INJECTION USP 6 MG — DIN 02320150
PACLITAXEL : 6 MG · SANDOZ CANADA INCORPORATED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PACLITAXEL INJECTION USP?
PACLITAXEL INJECTION USP 6 MG contains PACLITAXEL : 6 MG. It is listed in the Health Canada Drug Product Database under DIN 02320150, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Mar-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PACLITAXEL INJECTION USP used for?
Paclitaxel Injection USP is indicated, alone or in combination, for the treatment of carcinoma of the ovary, breast and lung. Ovarian Carcinoma - First-line treatment in combination with other chemotherapeutic agents. - Second-line treatment of metastatic carcinoma of the ovary after failure of standard therapy. Breast Carcinoma - Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy. In the clinical trial, there was an overall favourable effect on disease free and overall survival in the total population of patients with receptor-positive and receptor-negative tumours, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumours. (See PHARMACOLOGY, Clinical Trials). - Second-line treatment of metastatic carcinoma of the breast after failure of standard therapy. Lung Carcinoma - First-line treatment of advanced non-small cell lung cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Paclitaxel cost around the world?
Paclitaxel is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Brazil publishes a preco fabrica (ex-factory ceiling); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 123 | 130 | ZAR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 10 | 64 | BRL███.██ |
| Italy | ex-factory (classe H) | 15 | 25 | EUR███.██ |
| Morocco | PPV (public price) | 12 | 25 | MAD███.██ |
| Saudi Arabia | public | 8 | 16 | SAR███.██ |
| Romania | max producer price | 5 | 14 | RON███.██ |
| Czechia | max producer price (ex-factory) | 6 | 12 | CZK███.██ |
| Greece | producer price (ex-factory) | 11 | 11 | EUR███.██ |
| United Arab Emirates | public | 2 | 4 | AED███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Hungary | producer price (ex-factory) | 1 | 4 | HUF███.██ |
313 pack listings across 199 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Paclitaxel pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Paclitaxel in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
17 holders have a Canadian DIN containing Paclitaxel, across 19 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB CANADA | 2 | 1 | ABRAXANE FOR INJECTABLE SUSPENSION, TAXOL | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 1 | 1 | PACLITAXEL INJECTION USP | Sourceable in Canada |
| BIOLYSE PHARMA CORPORATION | 1 | 1 | PACLITAXEL FOR INJECTION | Sourceable in Canada |
| PANACEA BIOTEC PHARMA LIMITED | 1 | 1 | PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | PACLITAXEL INJECTION USP | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 0 | PACLITAXEL FOR INJECTION, TEVA-PACLITAXEL FOR INJECTION | No marketed DIN |
| BAKER NORTON PHARMACEUTICALS INC. | 1 | 0 | PAXENE | No marketed DIN |
| DRAXIS HEALTH INC. | 1 | 0 | PACLITAXEL INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | PACLITAXEL INJECTION | No marketed DIN |
| IMMUNEX CORPORATION | 1 | 0 | PACLITAXEL INJECTION | No marketed DIN |
| IVAX PHARMACEUTICALS INCORPORATED | 1 | 0 | PACLITAXEL | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | PACLITAXEL INJECTION, USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 6 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Paclitaxel Injection USP is available in multidose vials of 5 mL, 16.7 mL and Pharmacy Bulk Vial of 50 mL containing respectively 30 mg, 100 mg and 300 mg paclitaxel at a concentration of 6 mg/mL. |
| Storage | Paclitaxel Injection USP should be stored between 15 and 30 °C. Retain in the original package and protect from light. Once punctured, the 5 and 16.7 mL vials of Paclitaxel Injection USP are stable for 28 days at room temperature. The 50 mL Pharmacy Bulk Vial should be used within 24 hours after initial entry. Solutions for infusion prepared as recommended may be stored at room temperature (only if necessary). However, the infusion should be initiated within 24 hours of reconstitution. If unopened vials are refrigerated, a precipitate may form which redissolves with little or no agitation upon reaching room temperature. Product quality is not affected. If the solution remains cloudy or if an insoluble precipitate is noted, the vial should be discarded. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Paclitaxel |
|---|---|
| ATC code | L01CD01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02320150 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2320150 |
| Brand name | PACLITAXEL INJECTION USP |
| Generic / active ingredient | PACLITAXEL : 6 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | L01CD01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01CD |
| Current status | MARKETED |
| Status date | 31-Mar-2015 |
| Original market date | 2015-03-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Paclitaxel Injection USP should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Patients receiving Paclitaxel Injection USP should be pretreated with corticosteroids, antihistamines, and H2 antagonists (such as dexamethasone, diphenhydramine and cimetidine or ranitidine) to minimize hypersensitivity reactions. Paclitaxel Injection USP should be administered as a diluted infusion through an in-line filter with a microporous membrane not greater than 0.22 microns. Metastatic Carcinoma of the Ovary: - Primary treatment: 175 mg/m² over 3 hours in combination with cisplatin 75 mg/m² every 3 weeks. Paclitaxel should be given before cisplatin. - Previously treated: 175 mg/m² administered intravenously over 3 hours every 3 weeks. Carcinoma of the Breast: - Adjuvant treatment: 175 mg/m² intravenously over 3 hours every 3 weeks for four courses administered sequentially to standard combination therapy. - After failure of initial chemotherapy or relapse: 175 mg/m² administered intravenously over 3 hours every 3 weeks. Non-Small Cell Lung Carcinoma: - Recommended regimen: 175 mg/m² administered intravenously over 3 hours followed by cisplatin, every 3 weeks. Dosage Adjustment: - For severe neutropenia (<500 cells/mm³) or severe peripheral neuropathy, the dosage should be reduced by 20% for subsequent courses. - Single courses should not be repeated until neutrophil count is at least 1500 cells/mm³ and platelet count is at least 100,000 cells/mm³.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Paclitaxel is contraindicated in patients who have a history of severe hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor¹ EL (polyethoxylated castor oil). Paclitaxel should not be used in patients with severe baseline neutropenia (<1500 cells/mm³).
Warnings and precautions
Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Patients receiving Paclitaxel Injection USP should be pretreated with corticosteroids, antihistamines, and H2 antagonists to minimize hypersensitivity reactions. Severe hypersensitivity reactions, including anaphylaxis, dyspnea, hypotension, angioedema, and generalized urticaria, have occurred. Rare fatal reactions have occurred despite pretreatment. Patients who experience severe hypersensitivity reactions should not be rechallenged. Paclitaxel should not be administered to patients with baseline neutrophil counts of less than 1500 cells/mm³. Bone marrow suppression (primarily neutropenia) is dose and schedule dependent and is the dose-limiting toxicity. Frequent monitoring of blood counts is recommended. Patients should not be retreated until neutrophils recover to >1500 cells/mm³ and platelets to >100,000 cells/mm³. Severe cardiac conduction abnormalities have been reported in <1% of patients. If significant conduction abnormalities develop, appropriate therapy and continuous electrocardiographic monitoring should be performed. Paclitaxel may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should avoid becoming pregnant during therapy. Paclitaxel Injection USP contains dehydrated ethanol (401 mg/mL); consideration should be given to possible CNS and other effects of ethanol. Children may be more sensitive to the effects of ethanol.
Is Paclitaxel in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 11 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABRAXANE FOR INJECTABLE SUSPENSION | 100 MG | POWDER FOR SUSPENSION | BRISTOL-MYERS SQUIBB CANADA | MARKETED | 02281066 |
| PACLITAXEL FOR INJECTION | 6 MG | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | 02244372 |
| PACLITAXEL INJECTION USP | 6 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02391465 |
| PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL | 100 MG | POWDER FOR SUSPENSION | PANACEA BIOTEC PHARMA LIMITED | MARKETED | 02496097 |
| AJ-PACLITAXEL | 6 MG | SOLUTION | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | 02409712 |
| APO-PACLITAXEL INJECTABLE | 6 MG | SOLUTION | APOTEX INC | DORMANT | 02248844 |
| PACLITAXEL | 6 MG | LIQUID | IVAX PHARMACEUTICALS INCORPORATED | CANCELLED PRE MARKET | 02241314 |
| PACLITAXEL FOR INJECTION | 6 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | 02285363 |
| PACLITAXEL FOR INJECTION | 6 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02296624 |
| PACLITAXEL FOR INJECTION USP | 6 MG | SOLUTION | STERIMAX INC | DORMANT | 02320010 |
2 · Same class — other molecules in ATC L01CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Paclitaxel | ABRAXANE FOR INJECTABLE SUSPENSION · AJ-PACLITAXEL · APO-PACLITAXEL INJECTABLE · PACLITAXEL · +9 more | 19 | 5 | Yes |
| Cabazitaxel | CABAZITAXEL FOR INJECTION · JEVTANA | 7 | 5 | Yes |
| Docetaxel | ACT DOCETAXEL 40 MG/ML · DOCETAXEL INJECTION · DOCETAXEL INJECTION USP · PMS-DOCETAXEL · +2 more | 15 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01CE | Irinotecan · Topotecan | 32 | 12 |
| L01CA | Vinblastine · Vincristine · Vindesine · Vinorelbine | 22 | 7 |
| L01CB | Etoposide · Teniposide | 14 | 3 |
| L01CX | Trabectedin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PACLITAXEL INJECTION USP called?
Also recorded in Canada as: paclitaxel 100 MG Injection [Abraxane] (US), paclitaxel 6 MG/ML Injectable Solution (US), paclitaxel 100 MG Injection (US), PACLITAXEL (US), PACLITAXEL (AIBUMIN-BOUND) (US), PACLITAXEL PACLITAXEL (US), PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND (US), PACLITAXEL PROTEIN-BOUND PARTICLES (US), PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) (US), TAXOL (US), TAXOL (EU), TAXOL (UK), TAXOL (JP), TAXOL (KR), TAXOL (IN).
The same molecule, Paclitaxel, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PACLITAXEL | Latin | Brazil |
| MYLTOL | Latin | Brazil |
| TOXXEL | Latin | Brazil |
| Anzatax | Latin | Morocco, South Africa |
| Paclitaxel Kabi | Latin | Czechia, Saudi Arabia |
| ONTAX | Latin | Brazil |
| Paclitaxel Ebewe | Latin | Australia, Czechia |
| Taxol | Latin | Brazil, Morocco, South Africa |
| EBETAXEL | Latin | Morocco |
| EVOTAXEL | Latin | Brazil |
| ABRAXANE | Latin | Brazil, Czechia, Saudi Arabia |
| PANTIUM | Latin | Brazil |
| POKLI | Latin | Brazil |
| AZANTAX | Latin | Morocco |
| OKA-PACLITAXEL | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Paclitaxel called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Paclitaxel, published to help those searches reach this page.
| Language | Paclitaxel |
|---|---|
| Chinese (Simplified) 简体中文 | 紫杉醇 |
| Russian Русский | Паклитаксел |
| Spanish Español | Paclitaxel |
| French Français | Paclitaxel |
| Portuguese Português | Paclitaxel |
| German Deutsch | Paclitaxel |
| Japanese 日本語 | パクリタキセル |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.